NICOYA年衍药业
/
← All products

PRODUCTS

RAYALDEE®

Calcifediol extended-release capsules

An extended-release formulation of calcifediol and a key product in NICOYA's regional collaboration with OPKO.

Explore the product
RAYALDEE calcifediol extended-release capsules, front bottle view
Packaging varies by market. Refer to the actual local pack and locally approved labeling.

ABOUT RAYALDEE

Ingredient and formulation.

Ingredient
Calcifediol [25-hydroxyvitamin D₃]
Formulation and strength
Oral extended-release capsules; strength: 30 μg. See prescribing information.

Calcifediol is a precursor of active vitamin D and undergoes further activation before acting through these pathways.

  1. Extended-release formulation

    Calcifediol is delivered in an oral extended-release capsule.

  2. Further activation

    It is converted to calcitriol, primarily in the kidney.

  3. Receptor-mediated activity

    The active form acts through vitamin D receptor pathways involved in parathyroid hormone regulation.

RAYALDEE bottle from the supplied product campaign
RAYALDEEExtended-release formulation campaign illustration, not a photograph of the capsule interiorExtended-release concept
RAYALDEE · Product and formulation

CLINICAL STUDIES

Measures observed in clinical studies.

Two U.S. phase 3 trials enrolled 429 adults, and a Chinese phase 3 trial enrolled 100. Participants had stage 3 or 4 CKD, secondary hyperparathyroidism and vitamin D insufficiency; treatment lasted 26 weeks.

Vitamin D status

Patients with serum total 25(OH)D ≥ 30 ng/mL

RAYALDEEPlacebo
0%25%50%75%100%80.22.83001U.S.83.36.83002U.S.90.99.4ITTChina95.111.1PPSChina
26 weeks · Adults with stage 3 or 4 CKD. ITT: intention-to-treat; PPS: per-protocol set.
View chart values
Study / analysisRAYALDEEPlacebo
U.S. · 300180.2%2.8%
U.S. · 300283.3%6.8%
China · ITT90.9%9.4%
China · PPS95.1%11.1%

iPTH response in SHPT

Patients with an iPTH reduction ≥ 30% from baseline

RAYALDEEPlacebo
0%25%50%75%100%32.68.33001U.S.34.06.93002U.S.53.06.3ITTChina55.77.4PPSChina
26 weeks · Adults with stage 3 or 4 CKD. ITT: intention-to-treat; PPS: per-protocol set.
View chart values
Study / analysisRAYALDEEPlacebo
U.S. · 300132.6%8.3%
U.S. · 300234.0%6.9%
China · ITT53.0%6.3%
China · PPS55.7%7.4%

Study 3003 · Open-label extension

Patients with an iPTH reduction ≥ 30% at 52 weeks; both groups received ERC.

Continued ERC
49.2%
Placebo switched to ERC
33.0%
Primary endpoint

For the primary endpoint of at least 30% iPTH reduction, the U.S. trials reported 33% versus 8% and 34% versus 7%, RAYALDEE versus placebo. The Chinese ITT result was 53.0% versus 6.3%.

Safety and interpretation

Study results do not guarantee individual outcomes or establish approval in mainland China. Locally approved labeling governs use.

Prescribing information · Clinical Studies, section 14 ↗ASN Kidney Week 2025 · TH-PO1192 (conference abstract) ↗

Global regulatory progress

RAYALDEE approval records in more than 15 countries and regions, including the U.S., Canada, UK, other European countries, Israel, Macao and Hong Kong. Mainland China has submitted a marketing application, awaiting approval. Includes enlarged Europe and Hong Kong/Macao views.
United States2016.06.17 · Initial FDA approval
Europe11 countries · Marketing authorizations · disclosed in the 2025 annual report
Macao, China2024.11 · Marketing approval · disclosed by OPKO
Hong Kong, China2025.06 · Marketing approval · HK-68725
Mainland ChinaMarketing application submitted; awaiting approval
Approval records and jurisdictions

United States · Canada · Germany · Ireland · Italy · Spain · Denmark · Sweden · Norway · Portugal · Netherlands · Switzerland · United Kingdom · Israel · Macao, China · Hong Kong, China

Regional approvals do not imply uniform indications or uses. Refer to locally approved documents for applicable information.

USE AND SAFETY

Use and safety.

Indication
For treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency (serum total 25-hydroxyvitamin D below 30 ng/mL). See prescribing information.
Limitations of use
Not indicated for stage 5 chronic kidney disease or end-stage renal disease on dialysis. Safety and effectiveness in pediatric patients have not been established. Healthcare professionals should assess and monitor calcium, phosphorus, total 25-hydroxyvitamin D and intact parathyroid hormone (iPTH) according to the labeling. For contraindications, warnings and other safety information, see prescribing information.

Medicine information differs by jurisdiction. Refer to locally approved labeling and medical professionals for eligible patients, limitations and safety information. This website does not offer sales, prescriptions, individual medication advice or medical care.